The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Fri., Oct. 24, 11:25 PM

Slide #8. Tetraphase Pharmaceuticals, Inc. Secondary Offering

Company: Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)
Date announced: 10/15/2014
Shares Offered: 3,950,000
Date of Pricing: 10/16/2014
Price Per Share: $19.00
Secondary Offering Details: Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that it intends to offer and sell up to $75,000,000 of shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by Tetraphase. - updated 10/16 - Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the pricing of an underwritten public offering of 3,950,000 shares of common stock for a public offering price of $19.00 per share. The gross proceeds to Tetraphase from this offering are expected to be approximately $75 million, before deducting underwriting discounts and commissions and offering expenses payable by Tetraphase. Tetraphase has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 592,500 shares of common stock. All of the shares of common stock to be sold in the offering are to be sold by Tetraphase. The offering is expected to close on or about October 22, 2014, subject to customary closing conditions.

Tetraphase Pharmaceuticals is a clinical stage biopharmaceutical company using its proprietary chemistry technology to develop novel antibiotics for multidrug-resistant infections. Co.'s key product candidate, eravacycline, is a fully synthetic tetracycline derivative developed as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including Gram-negative infections. Co. is also pursuing the discovery and development of TP-271, a preclinical compound developed for respiratory diseases due to bacterial biothreat pathogens, and additional antibiotics to target multidrug-resistant Gram-negative bacteria.
Open the TTPH Page at The Online Investor »

Company Name:  Tetraphase Pharmaceuticals, Inc
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding TTPH:  14
Total Market Value Held by ETFs:  $15.59M
Total Market Capitalization:  $608.00M
% of Market Cap. Held by ETFs:  2.56%

Open the TTPH Page at The Online Investor (in a new window) »

October 24, 2014    11:25 PM Eastern
Quotes delayed 20 minutes

Strong Buy (3.86 out of 4)
84th percentile
(ranked higher than approx. 84% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.